A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS
Latest Information Update: 06 Aug 2024
At a glance
- Drugs Baricitinib (Primary)
- Indications Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Jul 2024 Planned End Date changed from 30 Apr 2025 to 1 Nov 2024.
- 17 Aug 2022 Planned End Date changed from 31 Oct 2023 to 30 Apr 2025.
- 14 Oct 2021 Status changed from recruiting to active, no longer recruiting.